Mackenzie Financial Corp Lowers Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Mackenzie Financial Corp lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 3.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,389,072 shares of the company's stock after selling 115,188 shares during the period. Mackenzie Financial Corp owned approximately 0.14% of Johnson & Johnson worth $531,203,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. 4J Wealth Management LLC lifted its stake in Johnson & Johnson by 2.2% in the fourth quarter. 4J Wealth Management LLC now owns 2,835 shares of the company's stock valued at $444,000 after buying an additional 62 shares in the last quarter. My Personal CFO LLC lifted its stake in Johnson & Johnson by 1.4% in the fourth quarter. My Personal CFO LLC now owns 4,550 shares of the company's stock valued at $713,000 after buying an additional 62 shares in the last quarter. Eagle Strategies LLC lifted its stake in Johnson & Johnson by 1.8% in the fourth quarter. Eagle Strategies LLC now owns 3,589 shares of the company's stock valued at $563,000 after buying an additional 63 shares in the last quarter. FIDELIS iM LLC lifted its stake in Johnson & Johnson by 3.1% in the fourth quarter. FIDELIS iM LLC now owns 2,117 shares of the company's stock valued at $374,000 after buying an additional 64 shares in the last quarter. Finally, Clearview Wealth Advisors LLC lifted its stake in Johnson & Johnson by 1.5% in the fourth quarter. Clearview Wealth Advisors LLC now owns 4,373 shares of the company's stock valued at $685,000 after buying an additional 64 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Analysts Set New Price Targets

A number of research firms have recently issued reports on JNJ. HSBC upgraded shares of Johnson & Johnson from a "hold" rating to a "buy" rating and lifted their price objective for the company from $169.00 to $170.00 in a report on Thursday. Bank of America lowered their target price on shares of Johnson & Johnson from $180.00 to $170.00 and set a "neutral" rating on the stock in a report on Wednesday. Cantor Fitzgerald restated an "overweight" rating and set a $215.00 target price on shares of Johnson & Johnson in a report on Monday, April 15th. StockNews.com upgraded shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a report on Tuesday, February 6th. Finally, Royal Bank of Canada lowered their target price on shares of Johnson & Johnson from $181.00 to $175.00 and set an "outperform" rating on the stock in a report on Wednesday. Seven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $175.86.

Insider Transactions at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 59,397 shares of the company's stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $156.27, for a total value of $9,281,969.19. Following the completion of the transaction, the executive vice president now owns 141,416 shares of the company's stock, valued at $22,099,078.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other Johnson & Johnson news, major shareholder & Johnson Johnson sold 3,725 shares of the stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the sale, the insider now owns 4,099,575 shares of the company's stock, valued at approximately $105,810,030.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Jennifer L. Taubert sold 59,397 shares of the stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the sale, the executive vice president now directly owns 141,416 shares of the company's stock, valued at approximately $22,099,078.32. The disclosure for this sale can be found here. Company insiders own 0.16% of the company's stock.

Johnson & Johnson Price Performance

JNJ traded up $2.17 on Friday, hitting $147.91. 9,750,751 shares of the stock were exchanged, compared to its average volume of 7,172,391. Johnson & Johnson has a 12 month low of $143.13 and a 12 month high of $175.97. The business has a 50-day moving average of $156.15 and a two-hundred day moving average of $155.63. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.16 and a quick ratio of 0.91. The firm has a market capitalization of $356.43 billion, a price-to-earnings ratio of 9.22, a PEG ratio of 2.44 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Tuesday, April 16th. The company reported $2.71 EPS for the quarter, topping analysts' consensus estimates of $2.64 by $0.07. The firm had revenue of $21.38 billion during the quarter, compared to analysts' expectations of $21.39 billion. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.43%. The business's revenue for the quarter was up 2.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.68 earnings per share. Sell-side analysts forecast that Johnson & Johnson will post 10.65 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st will be issued a $1.24 dividend. The ex-dividend date is Monday, May 20th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.35%. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.19. Johnson & Johnson's dividend payout ratio is 29.68%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.